Chronic lung disease · )
Nasal intermittent positive pressure ventilation (NIPPV) may leads to lower chronic lung disease compared with nasal continuous positive airway pressure (NCPAP) (by population) (low certainty).
1 finding from 1 review
Pneumothorax · )
Nasal intermittent positive pressure ventilation (NIPPV) showed no clear difference in pneumothorax compared with nasal continuous positive airway pressure (NCPAP) (by population) (low certainty).
1 finding from 1 review
Severe (grade 3 or greater) intraventricular hemorrhage (IVH) on cranial ultrasound ‐ not reported · )
Nasal intermittent positive pressure ventilation (NIPPV) showed no clear difference in severe intraventricular hemorrhage (grade III/IV) compared with nasal continuous positive airway pressure (NCPAP) (by population) (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · health problem or population
It is very uncertain whether summary of Findings Table ‐ Low changes death or BPD at 36 weeks PMA compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
1 finding from 1 review
BPD at 28 days · health problem or population
The review found no eligible studies for this question.
2 findings from 1 review
BPD (36 weeks' PMA) · health problem or population
It is very uncertain whether summary of Findings Table ‐ Low changes BPD, defined as supplemental oxygen or positive pressure support use… compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
1 finding from 1 review
Treatment failure or need for mechanical ventilation · health problem or population
It is very uncertain whether summary of Findings Table ‐ Low changes treatment failure or need for mechanical ventilation compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
2 findings from 1 review
Mortality before hospital discharge · health problem or population
It is very uncertain whether summary of Findings Table ‐ Low changes mortality, by hospital discharge compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
2 findings from 1 review
Moderate‐severe neurodevelopmental impairment at 18 to 26 months ‐ not measured · health problem or population
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia/chronic lung disease · health problem or population
It is very uncertain whether summary of Findings Table ‐ Low changes BPD, defined as supplemental oxygen or positive pressure support use… compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
1 finding from 1 review
Combined outcome of mortality or BPD at 36 weeks' PMA · health problem or population
It is very uncertain whether summary of Findings Table ‐ Low changes death or BPD at 36 weeks' PMA compared with moderate‐high nasal continuous positive airway pressure levels (very low certainty).
1 finding from 1 review
BPD at 28 days · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes BPD defined as an oxygen requirement at 28 days№ of participants:… compared with placebo (very low certainty).
1 finding from 1 review
RR 1.09 [0.94, 1.26]
Studies not reported
Very low
Bronchopulmonary dysplasia · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes BPD defined as oxygen at 36 weeks' postmenstrual age№ of… compared with placebo (very low certainty).
1 finding from 1 review
RR 0.96 [0.72, 1.29]
Studies not reported
Very low
Neonatal mortality · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes neonatal mortality (i.e. within 28 days)№ of participants: 335(2 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
RR 0.98 [0.57, 1.68]
Studies not reported
Very low
Mortality before hospital discharge · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes mortality prior to discharge№ of participants: 78(2 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
RR 1.2 [0.53, 2.71]
Studies not reported
Very low
BPD or death at 36 weeks' postmenstrual age№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for supplemental oxygen (days)№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Retinopathy of prematurity · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes retinopathy of prematurity№ of participants: 277(2 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
RR 0.95 [0.78, 1.15]
Studies not reported
Very low
Severe retinopathy of prematurity (stage II or greater)№ of participants: 244(1 RCT) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether superoxide dismutase (SOD) changes severe retinopathy of prematurity (stage II or greater)№ of… compared with placebo (very low certainty).
1 finding from 1 review
RR 0.97 [0.57, 1.65]
Studies not reported
Very low
Moderate to severe neurodevelopmental outcome at 18 to 24 months№ of participants: 0 (0 RCTs) · preterm infants at risk for bronchopulmonary dysplasia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found